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A novel 2-Butyl-4-chloro-5-formylimidazole thiosemicarbazone cobalt (II) complex is synthesized and
characterized by using spectroscopic techniques like elemental analysis, FT-IR, HRMS, electronic spectral
analysis and Powder-X-ray diffraction. The Co (II) complex is found to be highly efficient in inhibiting
the growth of human pathogens like S. aureus, B. megaterium with MIC value 12,0 g/mL whose inhibition
zones are almost comparable with the standard antibiotic. The synthesized complex well occupy in the active
site of -ketoacyl-acyl carrier protein synthase III enzyme (PDB: 1MZS), in consists of catalytic triad and
adenine-binding site, so the designed compounds are promising for to treat bacterial infection.
